SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Teva Pharmaceutical Industries Limited - TEVANewsfile Corp • 07/11/22
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022Business Wire • 06/29/22
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)Business Wire • 06/24/22
Nasdaq Bear Market: 3 of the Cheapest Stocks You Can Confidently Buy Right NowThe Motley Fool • 06/15/22
Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent DisputeBusiness Wire • 06/09/22
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual MeetingBusiness Wire • 06/09/22
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health ServicesBusiness Wire • 06/08/22
Teva Reaches Agreement With West Virginia to Settle the State's Opioid-Related ClaimsBusiness Wire • 05/25/22
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual MeetingBusiness Wire • 05/23/22